根据双方的协定，Abbvie和Calico将会首批分别斥资2.5亿美元投入合作，并在未来有望再分别投资5亿美元。
Calico将会负责未来5年内的药物研发以及未来10年内临床II期之前的项目开发，而Abbvie会负责前期协助Calico开发并负责临床II期研究之后的产品开发和上市。
Calico是由谷歌公司于1年之前成立，公司高管来源于已经被罗氏收购的基因泰克(Genetech)。
Calico, Google's biotech spinoff, forges $500M venture with AbbVieSAN FRANCISCO -- Google's ambitious health startup is teaming up with biotechnology drugmaker AbbVie in a $500 million joint venture that will try to develop new ways to treat cancer and other diseases such as Alzheimer's.
The alliance announced Wednesday calls for Google and AbbVie to each invest $250 million in the project. An additional $1 billion may be poured into the project. The two companies will split all expenses and any profits generated by the venture.
Calico, a company hatched by Mountain View-based Google last year, will manage a team of scientists who will work at a research-and-development lab in the San Francisco Bay Area. The precise location and size of the new lab hasn't been determined.
AbbVie, a spin-off from Abbott Laboratories, will oversee the marketing of the drugs. The North Chicago, Illinois, company already has been working on drugs to fight Parkinson's disease, Crohn's and other ailments.
Google set up Calico as separate business last year to pursue medical breakthroughs that would enable people to live longer. Toward that end, Calico is doing extensive research to get a better understanding about how the human body ages and working on technology that could cure cancer.
Calico is run by Arthur Levinson, a former CEO of biotech pioneer Genentech and a former member of Google's board. He is also chairman of Apple, which is expected to provide further details to help people manage their health next week when the company unveils its latest iPhone. The expansion into health also could include a new Apple device that could be worn on a person's wrist.
|手机版|药群论坛
( 蜀ICP备15007902号 )
收藏
支持
反对